MedImmune wins panel backing for expanded use of FluMist

MedImmune has won an expert panel vote to expand the use of FluMist to children. In a nine to six vote the panel concluded the benefits of the nasal spray outweighed the risks in children 1 to 5 years old with no known respiratory problems. MedImmune, which has agreed to a takeover bid from AstraZeneca, has been working to expand the market as well as ease of use of FluMist, which proved a colossal bomb when it was first approved in 2003.

- here's the report from CNN on MedImmune

ALSO: Shareholders of MedImmune have filed a class action lawsuit claiming that AstraZeneca's $15.6 billion deal is designed to benefit MedImmune's execs more than its shareholders. Report

Related story:
MedImmune boosted by new data on FluMist Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.